PMID- 37083962
OWN - NLM
STAT- MEDLINE
DCOM- 20230522
LR  - 20230522
IS  - 1432-5233 (Electronic)
IS  - 0940-5429 (Linking)
VI  - 60
IP  - 7
DP  - 2023 Jul
TI  - Diabetic patients with and without sodium-glucose cotransporter-2 inhibitors use 
      and cataract risk: real-world observational investigation.
PG  - 981-987
LID - 10.1007/s00592-023-02087-y [doi]
AB  - PURPOSE: We tried to define the association of type 2 diabetes mellitus (T2DM) 
      patients with and without sodium-glucose cotransporter-2 inhibitors (SGLT2I) use 
      and incident cataract using nationwide data in Taiwan. METHODS: In a Cox 
      proportional hazards regression model, we estimated the hazard ratios (HR) and 
      95% confidence intervals (95% CI). We considered risk factors for variables of 
      sex, age, comorbidities and medications that we adjusted in multivariable Cox 
      model. RESULTS: We identified 20,768 T2DM patients in this study; 10,384 patients 
      in the SGLT2I cohort, and 10,384 controls in the non-SGLT2I cohort. Compared with 
      the T2DM patients without SGLT2I, T2DM patients using SGLT2I had 
      a 2.04-fold increased risk of cataract, after adjustment by sex, age, 
      comorbidities and medications. CONCLUSION: Increased risk of cataract among 
      diabetic patients who took SGLT2I was found in this study.
CI  - (c) 2023. Springer-Verlag Italia S.r.l., part of Springer Nature.
FAU - Hu, Wei-Syun
AU  - Hu WS
AUID- ORCID: 0000-0003-2478-923X
AD  - School of Medicine, College of Medicine, China Medical University, Taichung, 
      40402, Taiwan. weisyunhu@gmail.com.
AD  - Division of Cardiovascular Medicine, Department of Medicine, China Medical 
      University Hospital, Taichung, 40447, Taiwan. weisyunhu@gmail.com.
FAU - Lin, Cheng-Li
AU  - Lin CL
AD  - Management Office for Health Data, China Medical University Hospital, Taichung, 
      40447, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20230421
PL  - Germany
TA  - Acta Diabetol
JT  - Acta diabetologica
JID - 9200299
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - IY9XDZ35W2 (Glucose)
RN  - 9NEZ333N27 (Sodium)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology
MH  - *Sodium-Glucose Transporter 2 Inhibitors/adverse effects
MH  - *Cataract/chemically induced/epidemiology
MH  - Glucose
MH  - Sodium/therapeutic use
OTO - NOTNLM
OT  - Cataract
OT  - Diabetes
OT  - SGLT2 inhibitor
EDAT- 2023/04/21 18:42
MHDA- 2023/05/22 06:42
CRDT- 2023/04/21 14:57
PHST- 2023/02/11 00:00 [received]
PHST- 2023/03/22 00:00 [accepted]
PHST- 2023/05/22 06:42 [medline]
PHST- 2023/04/21 18:42 [pubmed]
PHST- 2023/04/21 14:57 [entrez]
AID - 10.1007/s00592-023-02087-y [pii]
AID - 10.1007/s00592-023-02087-y [doi]
PST - ppublish
SO  - Acta Diabetol. 2023 Jul;60(7):981-987. doi: 10.1007/s00592-023-02087-y. Epub 2023 
      Apr 21.